Research Analysts’ Updated EPS Estimates for August, 29th (ABCO, ASAZY, ASBFY, AZPN, BAK, BGG, CEO, CLIGF, CLSN, CY)

Research Analysts’ updated eps estimates for Tuesday, August 29th:

The Advisory Board (NASDAQ:ABCO) was downgraded by analysts at Canaccord Genuity to a hold rating. Canaccord Genuity currently has $54.29 target price on the stock.

Assa Abloy AB (OTCMKTS:ASAZY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $12.00 price target on the stock. According to Zacks, “Assa Abloy AB offers locks and security products. Its product offer include mechanical locks such as door locks and cylinder locks and security doors, electromechanical locks, electronic locks, door closers, door automatics, access control systems. Assa Abloy also provides secure identity solutions, contactless identification technology solutions, electronic lock systems and safes for hotels and cruise ships. The Company primarily sells in Europe and in North America. Assa Abloy AB is based in Stockholm, Sweden. “

Associated British Foods plc (NASDAQ:ASBFY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $46.00 target price on the stock. According to Zacks, “Associated British Foods is a diversified international food, ingredients and retail group. The group is one of Europe’s largest food companies with a wide range of successful brands and products in the food sector, and an increasingly strong presence in advanced research and technology. “

Aspen Technology (NASDAQ:AZPN) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Aspen Technology Inc. is a recognized expert and leading provider of award-winning process optimization software and services. AspenTech’s integrated aspenONE solutions enable manufacturers to reduce costs, increase capacity, and optimize operational performance end-to-end throughout the engineering, plant operations, and supply chain management processes, resulting in millions of dollars in cost savings. “

Braskem (NYSE:BAK) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Braskem SA figures as the largest petrochemical operation in Latin America and among the five largest private companies in Brazil. With industrial facilities located in Alagoas, Bahia, São Paulo and Rio Grande do Sul, Braskem produces primary base petrochemicals such as ethylene, propylene, benzene, caprolactam, DMT and termoplastic resins (polypropylene, polyethylene, PVC and PET) gas and GLP. “

Briggs & Stratton Corporation (NYSE:BGG) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Briggs & Stratton Corp. is one of the world’s largest producers of air cooled gasoline engines for outdoor power equipment. The company designs, manufactures, markets and services these products for original equipment manufacturers worldwide. These engines are primarily aluminum alloy gasoline engines. “

CNOOC Limited (NYSE:CEO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Cnooc Limited is a company that engages primarily in the exploration, development and production of crude oil and natural gas offshore China. We are the dominant producer of crude oil and natural gas and the only company permitted to conduct exploration and production activities with international oil and gas companies offshore China. “

Clinigen Group Plc (NASDAQ:CLIGF) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Celsion Corporation (NASDAQ:CLSN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $1.50 price target on the stock. According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “

Cypress Semiconductor Corporation (NASDAQ:CY) had its buy rating reissued by analysts at Mizuho. They currently have a $17.00 price target on the stock. The analysts wrote, “We would use the pullback as a buying opportunity today. CY should see continued upside with Automotive tailwinds but also Nintendo Switch (~$5+ content) strong demand. We believe near-term Nintendo Switch demand remains strong.””

ImmunoGen (NASDAQ:IMGN) had its hold rating reaffirmed by analysts at Cowen and Company. The analysts wrote, “IMGN announced a collaboration agreement with Jazz for the development and.””